Nuvectis Pharma (NVCT)
Nuvectis Pharma on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.4M
Short interest
settlement 2026-10-15
13.9
Days to cover
+3.6 days vs prior
67.4%
Short share of volume
2026-11-02
3,141
Fails to deliver
settlement 2026-10-09
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NVCT is 2,400,867 shares, up 38,340 shares over the last month. Over the last 48 readings it ranged from 854,558 shares (15 September 2025) to 2,644,379 shares (15 July 2025). At the reported average volume of 172K shares a day that is 13.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nvct" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,400,867 | -4.8% | 172,359 | 13.93 |
| 2026-09-30 | 2,522,106 | +6.8% | 243,827 | 10.34 |
| 2026-09-15 | 2,362,527 | +7.6% | 159,989 | 14.77 |
| 2026-08-31 | 2,196,224 | +19.6% | 235,465 | 9.33 |
| 2026-08-14 | 1,836,385 | -0.4% | 200,616 | 9.15 |
| 2026-07-31 | 1,843,596 | +21.9% | 249,062 | 7.40 |
| 2026-07-15 | 1,512,192 | -16.1% | 377,728 | 4.00 |
| 2026-06-30 | 1,802,732 | +14.9% | 788,911 | 2.29 |
| 2026-06-15 | 1,568,991 | -0.8% | 69,334 | 22.63 |
| 2026-05-29 | 1,580,880 | +10.8% | 116,044 | 13.62 |
| 2026-05-15 | 1,426,480 | -2.6% | 130,238 | 10.95 |
| 2026-04-30 | 1,464,074 | -5.0% | 49,114 | 29.81 |
| 2026-04-15 | 1,541,168 | -2.2% | 49,240 | 31.30 |
| 2026-03-31 | 1,575,869 | -2.7% | 68,516 | 23.00 |
| 2026-03-13 | 1,619,688 | -0.0% | 53,750 | 30.13 |
| 2026-02-27 | 1,620,407 | -1.5% | 36,560 | 44.32 |
| 2026-02-13 | 1,645,122 | +3.2% | 70,201 | 23.43 |
| 2026-01-30 | 1,593,652 | -1.4% | 57,505 | 27.71 |
| 2026-01-15 | 1,615,597 | +5.4% | 89,249 | 18.10 |
| 2025-12-31 | 1,532,728 | +7.2% | 78,146 | 19.61 |
| 2025-12-15 | 1,430,312 | +4.1% | 102,683 | 13.93 |
| 2025-11-28 | 1,374,419 | +3.6% | 81,449 | 16.87 |
| 2025-11-14 | 1,325,985 | +7.9% | 92,857 | 14.28 |
| 2025-10-31 | 1,229,398 | +36.5% | 134,521 | 9.14 |
| 2025-10-15 | 900,775 | -8.8% | 68,221 | 13.20 |
| 2025-09-30 | 987,672 | +15.6% | 106,425 | 9.28 |
| 2025-09-15 | 854,558 | -13.1% | 73,467 | 11.63 |
| 2025-08-29 | 982,835 | -3.2% | 57,570 | 17.07 |
| 2025-08-15 | 1,015,746 | -4.6% | 151,061 | 6.72 |
| 2025-07-31 | 1,064,421 | -59.8% | 266,727 | 3.99 |
| 2025-07-15 | 2,644,379 | +0.1% | 87,350 | 30.27 |
| 2025-06-30 | 2,640,426 | +24.4% | 280,877 | 9.40 |
| 2025-06-13 | 2,122,693 | +0.6% | 97,866 | 21.69 |
| 2025-05-30 | 2,109,698 | +0.3% | 118,748 | 17.77 |
| 2025-05-15 | 2,102,399 | +11.3% | 136,918 | 15.36 |
| 2025-04-30 | 1,888,846 | +15.7% | 186,678 | 10.12 |
| 2025-04-15 | 1,632,838 | +0.3% | 108,378 | 15.07 |
| 2025-03-31 | 1,627,920 | +9.3% | 157,069 | 10.36 |
| 2025-03-14 | 1,489,076 | +10.9% | 91,963 | 16.19 |
| 2025-02-28 | 1,342,116 | -13.8% | 82,304 | 16.31 |
| 2025-02-14 | 1,557,551 | +5.0% | 175,555 | 8.87 |
| 2025-01-31 | 1,482,776 | +0.4% | 77,072 | 19.24 |
| 2025-01-15 | 1,477,329 | +4.1% | 120,124 | 12.30 |
| 2024-12-31 | 1,418,996 | -1.8% | 110,095 | 12.89 |
| 2024-12-13 | 1,444,440 | +1.7% | 76,654 | 18.84 |
| 2024-11-29 | 1,420,289 | +1.8% | 139,926 | 10.15 |
| 2024-11-15 | 1,394,796 | +23.4% | 414,687 | 3.36 |
| 2024-10-31 | 1,130,105 | +8.0% | 201,839 | 5.60 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of NVCT volume is 67.4%, down 14.1 points over the last five sessions. Over the last 30 readings it ranged from 51.0% (29 October 2026) to 83.2% (22 October 2026). The latest reading is 2.4 points below the 30-session average of 69.8%, on 79K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 53K | 79K | 67.4% | 0 |
| 2026-10-30 | 41K | 70K | 58.1% | 0 |
| 2026-10-29 | 27K | 53K | 51.0% | 0 |
| 2026-10-28 | 49K | 82K | 59.0% | 0 |
| 2026-10-27 | 42K | 61K | 68.1% | 908 |
| 2026-10-26 | 99K | 122K | 81.5% | 706 |
| 2026-10-23 | 27K | 34K | 79.2% | 0 |
| 2026-10-22 | 28K | 34K | 83.2% | 0 |
| 2026-10-21 | 60K | 84K | 71.3% | 3 |
| 2026-10-20 | 42K | 57K | 73.6% | 0 |
| 2026-10-19 | 66K | 108K | 60.7% | 0 |
| 2026-10-16 | 49K | 65K | 74.8% | 0 |
| 2026-10-15 | 63K | 77K | 82.7% | 0 |
| 2026-10-14 | 31K | 54K | 57.2% | 0 |
| 2026-10-13 | 52K | 84K | 62.4% | 103 |
| 2026-10-12 | 34K | 56K | 61.1% | 0 |
| 2026-10-09 | 43K | 52K | 81.3% | 0 |
| 2026-10-08 | 28K | 51K | 54.3% | 0 |
| 2026-10-07 | 25K | 40K | 61.8% | 0 |
| 2026-10-06 | 54K | 67K | 80.2% | 0 |
| 2026-10-05 | 45K | 73K | 61.1% | 0 |
| 2026-10-02 | 48K | 58K | 82.7% | 0 |
| 2026-10-01 | 46K | 64K | 71.5% | 0 |
| 2026-09-30 | 35K | 51K | 69.5% | 0 |
| 2026-09-29 | 44K | 58K | 75.8% | 0 |
| 2026-09-28 | 36K | 47K | 77.4% | 0 |
| 2026-09-25 | 42K | 74K | 56.3% | 0 |
| 2026-09-24 | 80K | 106K | 75.8% | 0 |
| 2026-09-23 | 53K | 65K | 81.8% | 400 |
| 2026-09-22 | 32K | 44K | 72.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in NVCT is 3,141 shares, down 2,437 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (17 August 2026) to 383,126 shares (8 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 3,141 | $20.13 | $63K |
| 2026-10-05 | 5,578 | $21.92 | $122K |
| 2026-10-02 | 170 | $20.72 | $4K |
| 2026-10-01 | 2,647 | $21.12 | $56K |
| 2026-09-29 | 168 | $20.81 | $3K |
| 2026-09-25 | 3,648 | $21.63 | $79K |
| 2026-08-24 | 400 | $23.56 | $9K |
| 2026-08-20 | 4,821 | $23.33 | $112K |
| 2026-08-17 | 3 | $18.96 | $57 |
| 2026-08-10 | 5,480 | $18.95 | $104K |
| 2026-08-06 | 1,891 | $19.26 | $36K |
| 2026-08-05 | 1,849 | $20.10 | $37K |
| 2026-08-03 | 160 | $21.52 | $3K |
| 2026-07-31 | 2,692 | $22.76 | $61K |
| 2026-07-30 | 87,059 | $20.69 | $1.8M |
| 2026-07-29 | 41,704 | $19.82 | $827K |
| 2026-07-28 | 42,370 | $19.54 | $828K |
| 2026-07-27 | 41,704 | $19.31 | $805K |
| 2026-07-24 | 30,304 | $20.15 | $611K |
| 2026-07-23 | 2,327 | $19.29 | $45K |
| 2026-07-21 | 319,403 | $18.03 | $5.8M |
| 2026-07-20 | 319,308 | $19.14 | $6.1M |
| 2026-07-17 | 319,203 | $18.60 | $5.9M |
| 2026-07-16 | 361,903 | $19.59 | $7.1M |
| 2026-07-15 | 362,004 | $18.29 | $6.6M |
| 2026-07-14 | 362,889 | $18.44 | $6.7M |
| 2026-07-13 | 364,305 | $18.35 | $6.7M |
| 2026-07-10 | 380,254 | $18.99 | $7.2M |
| 2026-07-09 | 377,160 | $18.75 | $7.1M |
| 2026-07-08 | 383,126 | $19.20 | $7.4M |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for NVCT in the last 90 days. The most recent filings are listed below. Latest filing: Carson Michael J. (Vice President, Finance) on 2026-08-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. | Vice President, Finance | Grant | 30K | $0.00 | $0 | 230K |
| 2026-06-30 | Mosseri Marlio Charles | 10% owner | Buy | 50K | $18.32 | $916K | 3.2M |
| 2026-06-30 | BENTSUR RON | Chairman & CEO | Buy | 13K | $20.00 | $250K | 3.7M |
| 2026-06-11 | Kaplan Matthew L. | Director | Grant | 35K | $0.00 | $0 | 160K |
| 2026-06-11 | Sanchez Juan | Director | Grant | 35K | $0.00 | $0 | 113K |
| 2026-06-11 | Oliviero James F III | Director | Grant | 35K | $0.00 | $0 | 123K |
| 2026-06-11 | Hoberman Kenneth | Director | Grant | 35K | $0.00 | $0 | 168K |
| 2026-01-06 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant | 150K | $0.00 | $0 | 1.8M |
| 2026-01-06 | Poradosu Enrique | Chief Science & Business Off | Grant | 150K | $0.00 | $0 | 1.8M |
| 2026-01-06 | Carson Michael J. | Vice President, Finance | Grant | 61K | $0.00 | $0 | 200K |
| 2026-01-06 | BENTSUR RON | Chairman & CEO | Grant | 150K | $0.00 | $0 | 3.7M |
| 2025-11-05 | Sanchez Juan | Director | Buy | 13K | $5.79 | $75K | 78K |
| 2025-11-05 | Kaplan Matthew L. | Director | Buy | 11K | $5.84 | $64K | 125K |
| 2025-11-05 | BENTSUR RON | Chairman & CEO | Buy | 5K | $5.72 | $29K | 3.5M |
| 2025-10-27 | Mosseri Marlio Charles | 10% owner | Buy | 73K | $6.28 | $457K | 3.1M |
| 2025-10-24 | Mosseri Marlio Charles | 10% owner | Buy | 35K | $6.15 | $215K | 3.1M |
| 2025-10-23 | Mosseri Marlio Charles | 10% owner | Buy | 47K | $6.06 | $284K | 3.0M |
| 2025-09-22 | Sanchez Juan | Director | Grant | 30K | $0.00 | $0 | 65K |
| 2025-06-20 | Mosseri Marlio Charles | 10% owner | Buy | 6K | $7.99 | $45K | 3.0M |
| 2025-06-18 | Mosseri Marlio Charles | 10% owner | Buy | 28K | $8.05 | $226K | 3.0M |
| 2025-06-17 | Mosseri Marlio Charles | 10% owner | Buy | 5K | $8.11 | $44K | 2.9M |
| 2025-06-12 | Oliviero James F III | Director | Grant | 30K | $0.00 | $0 | 88K |
| 2025-06-12 | Kaplan Matthew L. | Director | Grant | 30K | $0.00 | $0 | 114K |
| 2025-06-12 | Hoberman Kenneth | Director | Grant | 30K | $0.00 | $0 | 133K |
| 2025-05-12 | Mosseri Marlio Charles | TenPercentOwner | Buy | 21K | $8.11 | $172K | 2.9M |
| 2025-05-09 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $8.95 | $88K | 2.9M |
| 2025-05-09 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $8.90 | $87K | 2.9M |
| 2025-05-09 | Mosseri Marlio Charles | TenPercentOwner | Buy | 5K | $8.98 | $48K | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | 10% owner | Buy | 100 | $8.65 | $865 | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | TenPercentOwner | Buy | 100 | $8.65 | $865 | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | TenPercentOwner | Buy | 2K | $8.65 | $21K | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | TenPercentOwner | Buy | 50 | $8.65 | $433 | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | TenPercentOwner | Buy | 100 | $8.71 | $871 | 2.9M |
| 2025-05-08 | Mosseri Marlio Charles | TenPercentOwner | Buy | 2K | $8.97 | $22K | 2.9M |
| 2025-05-07 | Mosseri Marlio Charles | TenPercentOwner | Buy | 3K | $8.40 | $23K | 2.9M |
| 2025-05-07 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $8.64 | $83K | 2.9M |
| 2025-05-06 | Mosseri Marlio Charles | TenPercentOwner | Buy | 2K | $8.40 | $20K | 2.9M |
| 2025-05-06 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $8.64 | $87K | 2.9M |
| 2025-02-07 | Mosseri Marlio Charles | TenPercentOwner | Buy | 240K | $5.00 | $1.2M | 2.9M |
| 2025-01-02 | BENTSUR RON | Chairman & CEO | Grant | 250K | $0.00 | $0 | 3.5M |
| 2025-01-02 | Carson Michael J. | Vice President, Finance | Grant | 51K | $0.00 | $0 | 139K |
| 2025-01-02 | Poradosu Enrique | Chief Science & Business Off | Grant | 150K | $0.00 | $0 | 1.7M |
| 2025-01-02 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant | 150K | $0.00 | $0 | 1.6M |
| 2024-12-24 | BENTSUR RON | Chairman & CEO | Buy | 5K | $4.65 | $21K | 3.3M |
| 2024-12-13 | Mosseri Marlio Charles | TenPercentOwner | Buy | 17K | $4.70 | $80K | 2.6M |
| 2024-12-13 | Mosseri Marlio Charles | TenPercentOwner | Buy | 17K | $4.70 | $80K | 2.6M |
| 2024-12-12 | Mosseri Marlio Charles | TenPercentOwner | Buy | 32K | $4.64 | $149K | 2.6M |
| 2024-11-19 | Poradosu Enrique | Chief Science & Business Off | Buy | 2K | $4.99 | $10K | 1.5M |
| 2024-11-15 | BENTSUR RON | Chairman & CEO | Buy | 20K | $4.92 | $98K | 3.3M |
| 2024-11-07 | Carson Michael J. | Vice President, Finance | Sell | 3K | $8.16 | $22K | 88K |
| 2024-06-13 | Oliviero James F III | Director | Grant | 30K | $0.00 | $0 | 58K |
| 2024-06-13 | Hoberman Kenneth | Director | Grant | 30K | $0.00 | $0 | 103K |
| 2024-06-13 | Kaplan Matthew L. | Director | Grant | 30K | $0.00 | $0 | 84K |
| 2024-05-14 | BENTSUR RON | Chairman & CEO | Buy | 2K | $6.74 | $13K | 3.2M |
| 2024-05-10 | Shemesh Shay | Chief Dev. & Ops. Officer | Buy | 1K | $6.32 | $7K | 1.5M |
| 2024-05-10 | Poradosu Enrique | Chief Science & Business Off | Buy | 500 | $6.29 | $3K | 1.5M |
| 2024-05-10 | BENTSUR RON | Chairman & CEO | Buy | 2K | $6.40 | $13K | 3.2M |
| 2024-03-18 | BENTSUR RON | Chairman & CEO | Buy | 5K | $10.29 | $51K | 3.2M |
| 2024-01-04 | Carson Michael J. | Vice President, Finance | Grant | 35K | $0.00 | $0 | 91K |
| 2024-01-03 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant | 130K | $0.00 | $0 | 1.5M |
| 2024-01-03 | Poradosu Enrique | Chief Science & Business Off | Grant | 130K | $0.00 | $0 | 1.5M |
| 2023-10-10 | BENTSUR RON | Chairman & CEO | Buy | 640 | $11.08 | $7K | 3.2M |
| 2023-10-09 | BENTSUR RON | Chairman & CEO | Buy | 830 | $11.19 | $9K | 3.2M |
| 2023-10-06 | BENTSUR RON | Chairman & CEO | Buy | 250 | $11.27 | $3K | 3.2M |
| 2023-10-05 | BENTSUR RON | Chairman & CEO | Buy | 1K | $11.09 | $16K | 3.2M |
| 2023-10-04 | BENTSUR RON | Chairman & CEO | Buy | 2K | $10.95 | $20K | 3.2M |
| 2023-08-16 | BENTSUR RON | Chairman & CEO | Buy | 115 | $15.15 | $2K | 3.2M |
| 2023-08-15 | BENTSUR RON | Chairman & CEO | Buy | 235 | $14.34 | $3K | 3.2M |
| 2023-08-11 | BENTSUR RON | Chairman & CEO | Buy | 180 | $14.66 | $3K | 3.2M |
| 2023-08-08 | BENTSUR RON | Chairman & CEO | Buy | 120 | $14.83 | $2K | 3.2M |
| 2023-07-31 | Mosseri Marlio Charles | TenPercentOwner | Buy | 860 | $13.88 | $12K | 2.6M |
| 2023-07-28 | Mosseri Marlio Charles | TenPercentOwner | Buy | 3K | $13.91 | $36K | 2.6M |
| 2023-07-27 | Mosseri Marlio Charles | TenPercentOwner | Buy | 2K | $13.98 | $22K | 2.6M |
| 2023-07-26 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $13.97 | $140K | 2.6M |
| 2023-07-21 | Mosseri Marlio Charles | TenPercentOwner | Buy | 3K | $14.61 | $42K | 2.6M |
| 2023-07-21 | BENTSUR RON | Chairman & CEO | Buy | 225 | $14.85 | $3K | 3.2M |
| 2023-07-20 | Mosseri Marlio Charles | TenPercentOwner | Buy | 5K | $14.40 | $78K | 2.6M |
| 2023-07-20 | BENTSUR RON | Chairman & CEO | Buy | 110 | $15.06 | $2K | 3.2M |
| 2023-07-19 | BENTSUR RON | Chairman & CEO | Buy | 200 | $14.33 | $3K | 3.2M |
| 2023-07-19 | Mosseri Marlio Charles | TenPercentOwner | Buy | 8K | $14.84 | $119K | 2.6M |
| 2023-07-18 | Mosseri Marlio Charles | TenPercentOwner | Buy | 9K | $14.84 | $136K | 2.6M |
| 2023-07-14 | BENTSUR RON | Chairman & CEO | Buy | 150 | $15.03 | $2K | 3.2M |
| 2023-07-12 | Mosseri Marlio Charles | TenPercentOwner | Buy | 3K | $15.09 | $50K | 2.6M |
| 2023-07-11 | Mosseri Marlio Charles | TenPercentOwner | Buy | 10K | $15.36 | $154K | 2.6M |
| 2023-07-07 | Mosseri Marlio Charles | TenPercentOwner | Buy | 9K | $15.19 | $136K | 2.5M |
| 2023-07-07 | BENTSUR RON | Chairman & CEO | Buy | 110 | $16.19 | $2K | 3.2M |
| 2023-07-06 | BENTSUR RON | Chairman & CEO | Buy | 320 | $14.88 | $5K | 3.2M |
| 2023-07-06 | Mosseri Marlio Charles | TenPercentOwner | Buy | 3K | $15.01 | $48K | 2.5M |
| 2023-07-05 | Mosseri Marlio Charles | TenPercentOwner | Buy | 1K | $15.52 | $18K | 2.5M |
| 2023-06-26 | BENTSUR RON | Chairman & CEO | Buy | 750 | $16.50 | $12K | 3.2M |
| 2023-06-26 | Mosseri Marlio Charles | TenPercentOwner | Buy | 17K | $16.46 | $276K | 2.5M |
| 2023-06-23 | Mosseri Marlio Charles | TenPercentOwner | Buy | 73K | $17.43 | $1.3M | 2.5M |
| 2023-06-22 | Mosseri Marlio Charles | TenPercentOwner | Buy | 7K | $17.73 | $124K | 2.4M |
| 2023-06-21 | BENTSUR RON | Chairman & CEO | Buy | 500 | $17.88 | $9K | 3.2M |
| 2023-06-21 | Mosseri Marlio Charles | TenPercentOwner | Buy | 6K | $17.71 | $108K | 2.4M |
| 2023-06-16 | Hoberman Kenneth | Director | Grant | 18K | $0.00 | $0 | 73K |
| 2023-06-16 | Kaplan Matthew L. | Director | Grant | 18K | $0.00 | $0 | 54K |
| 2023-06-16 | Oliviero James F III | Director | Grant | 18K | $0.00 | $0 | 28K |
| 2023-06-16 | Mosseri Marlio Charles | TenPercentOwner | Buy | 13K | $17.75 | $225K | 2.4M |
| 2023-06-15 | Mosseri Marlio Charles | TenPercentOwner | Buy | 32K | $17.71 | $562K | 2.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of NVCT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Levy Guy at 5.1% of the class (1,648,024 shares), filed 2026-08-06 for an event on 2026-08-04.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G | Levy Guyindividual | 1.6M | 5.1% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Capital Management, L.P.partnership | 1.6M | 5.1% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus GP, LLCother entity | 1.6M | 5.1% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Capital, LLCother entity | 1.5M | 4.6% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Capital Master Fund, L.P.non-US institution | 1.5M | 4.6% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Capital Group, LLCother entity | 1.5M | 4.6% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Private Equity Fund III, L.P.partnership | 150K | 0.5% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus PE GP III, LLCother entity | 150K | 0.5% | 2026-08-04 |
| 2026-08-06 | 13G | Soleus Private Equity GP III, LLCother entity | 150K | 0.5% | 2026-08-04 |
13F holders
Tracked managers holding NVCT at their latest 13F. JSON2 of the 30 tracked managers held NVCT at their latest 13F, $2.7M in total at quarter-end prices. Citadel Advisors is the largest at $2.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 116K | $2.1M | 0.00% | +37K |
| AQR Capital Management | 2026-06-30 | 32K | $586K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Nuvectis Pharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Nuvectis Pharma (NVCT), SEC CIK 1875558, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1875558Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of NVCT is sold short?
2,400,867 shares were held short at the 2026-10-15 settlement, 13.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NVCT's daily short volume?
On 2026-11-02, 53,275 of the 79,083 NVCT shares reported to FINRA were sold short, 67.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NVCT have fails to deliver?
The SEC's latest file shows 3,141 NVCT shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are NVCT insiders buying or selling?
No open-market insider trades were reported for NVCT in the last 90 days. The most recent filings are listed below. Latest filing: Carson Michael J. (Vice President, Finance) on 2026-08-03.
Who owns 5% or more of NVCT?
3 holders report 5% or more of NVCT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Levy Guy at 5.1% of the class (1,648,024 shares), filed 2026-08-06 for an event on 2026-08-04.
Which tracked 13F managers own NVCT?
2 of the 30 tracked 13F managers held NVCT shares at their latest filing, $2.7M in all. The largest: Ken Griffin's Citadel Advisors (116K shares, $2.1M), Cliff Asness's AQR Capital Management (32K shares, $586K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.